Table 3. Clinical events 30 days or 1 year or 3 years later .
| Group 1 (43) | Group 2 (124) | Group 3 (97) | p-value | |
| Mean follow-up days | 1626 ± 931 | 1568 ± 712 | 1706 ± 818 | 0.439 |
| Lost follow-up rate after 3-years (%) | 9.3 | 8.9 | 15.5 | 0.277 |
| 30-day | ||||
| Major adverse cardiac event (%) | 0 | 1.6 | 3.3 | 0.402 |
| Recurrent myocardial infarction (%) | 0 | 0.8 | 1.3 | 0.404 |
| Target-vessel revascularization (%) | 0 | 0.8 | 0 | 0.631 |
| Cardiovascular mortality (%) | 0 | 0.8 | 2.1 | 0.508 |
| 1-year | ||||
| Major adverse cardiac event (%) | 7.0 | 13.7 | 10.9 | 0.476 |
| Recurrent myocardial infarction (%) | 2.9 | 3.5 | 2.6 | 0.923 |
| Target-vessel revascularization (%) | 6.7 | 14.8 | 9.6 | 0.436 |
| Cardiovascular mortality (%) | 0 | 0.8 | 2.4 | 0.512 |
| 3-year | ||||
| Major adverse cardiac event (%) | 11.6 | 21.0 | 17.4 | 0.381 |
| Recurrent myocardial infarction (%) | 6.3 | 6.4 | 9.2 | 0.776 |
| Target-vessel revascularization (%) | 7.0 | 19.4 | 15.1 | 0.548 |
| Cardiovascular mortality (%) | 0 | 1.6 | 3.1 | 0.442 |
* Plus-minus values are means ± SD; Group 1: nitroprusside; Group 2: thrombectomy; Group 3: control.
* Data expressed as % (n) of patients.
* Different letters (a, b, c) associated with different groups indicate significant difference (at 0.05 level) by Bonferroni multiple comparison procedure.